Indivior (INDV) AI Stock Analysis

• Market Cap: $4.00B
• Dividend Yield: N/A
• Average Volume (3M): 2.06M
• Price to Earnings (P/E): 31.9
• Beta (1Y): 0.62
• Revenue Growth: -0.25%
• EPS Growth: N/A
• Country: US
• Employees: 1,030
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.72
• Shares Outstanding: 124,853,900
• 10 Day Avg. Volume: 3,013,236
• 30 Day Avg. Volume: 2,059,888
• PEG Ratio: 239.55
• Price to Book (P/B): -4.71
• Price to Sales (P/S): 1.38
• P/FCF Ratio: 234.39
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 2.56
• Enterprise Value/Gross Profit: 3.18
• Enterprise Value/Ebitda: 10.31
• 1Y Price Target: $39.25
• Price Target Upside: 22.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $31.00 ▼(-3.13% Downside)

Indivior's overall stock score is driven by strong earnings call results and positive technical indicators, despite valuation concerns and financial stability issues. The company's growth prospects and strategic initiatives are promising, but high leverage and overvaluation pose risks.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market reach and increasing demand for Indivior's products, supporting long-term business viability.

Strategic Initiatives

The Action Agenda aims to streamline operations and reduce costs, which can enhance operational efficiency and drive sustainable growth.

Market Position

A stable market share for SUBLOCADE demonstrates strong competitive positioning in the opioid treatment market, supporting future revenue stability.

Negative Factors

Balance Sheet Challenges

Negative equity and high leverage indicate financial instability, which can limit the company's ability to invest in growth and weather economic downturns.

Pricing Pressure

Pricing pressure on key products like SUBOXONE Film can erode margins and impact profitability, challenging long-term financial performance.

Operational Efficiency

Limited operational efficiency can hinder the company's ability to maximize profitability and compete effectively, impacting long-term growth prospects.

Indivior Business Overview & Revenue Model

Company Description

Indivior PLC is a global pharmaceutical company focused on the treatment of substance use disorders and mental health conditions. Established as a spinoff from Reckitt Benckiser in 2014, Indivior specializes in developing innovative medications that address opioid dependence, with its flagship product being Suboxone, a combination of buprenorphine and naloxone. The company operates primarily in the healthcare sector, working to improve patient outcomes through its proprietary therapies and support programs for addiction treatment.

How the Company Makes Money

Indivior generates revenue primarily through the sale of its prescription medications, particularly Suboxone and its generics. The company operates under a direct sales model, distributing its products through healthcare providers and pharmacies. Key revenue streams include sales from Suboxone film and tablet formulations, as well as emerging products in the pipeline aimed at treating opioid use disorder. Additionally, Indivior benefits from partnerships with healthcare organizations and government programs that facilitate access to its treatments. Regulatory approvals and market exclusivity also play a significant role in sustaining its revenue, alongside strategic initiatives to expand its product offerings in addiction treatment and mental health.

Indivior Financial Statement Overview

Summary

Indivior shows strong revenue growth and improved profitability, but faces significant balance sheet challenges with negative equity and high leverage. Cash flow management is mixed, with declining free cash flow growth but improved cash conversion ratios.

Income Statement

Indivior's income statement shows a strong gross profit margin of 82.8% TTM, indicating efficient cost management. The net profit margin improved significantly to 14.1% TTM from near breakeven levels in previous years, reflecting enhanced profitability. Revenue growth is robust at 59.6% TTM, showcasing strong sales momentum. However, EBIT and EBITDA margins, while improved, still suggest room for operational efficiency gains.

Balance Sheet

The balance sheet reveals a concerning negative stockholders' equity, leading to a negative debt-to-equity ratio. This indicates potential financial instability and high leverage risk. Return on equity is negative, highlighting challenges in generating returns for shareholders. The equity ratio is also negative, suggesting a reliance on debt financing.

Cash Flow

Cash flow analysis shows a decline in free cash flow growth by 30.7% TTM, indicating potential liquidity issues. However, the operating cash flow to net income ratio improved to 0.20 TTM, suggesting better cash conversion. The free cash flow to net income ratio of 0.69 TTM indicates a reasonable level of cash generation relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.18B	1.19B	1.09B	884.63M	777.48M	689.68M
Gross Profit	949.00M	957.00M	907.00M	715.75M	639.87M	573.49M
EBITDA	293.00M	84.00M	68.61M	-44.18M	233.93M	-128.98M
Net Income	166.00M	2.00M	2.00M	-52.04M	205.00M	-157.76M
Balance Sheet
Total Assets	1.42B	1.32B	1.95B	1.78B	1.83B	1.53B
Cash, Cash Equivalents and Short-Term Investments	445.00M	320.00M	410.00M	897.83M	1.10B	858.00M
Total Debt	52.00M	375.00M	282.00M	278.50M	285.44M	285.00M
Total Liabilities	1.62B	1.67B	1.95B	1.73B	1.63B	1.45B
Stockholders Equity	-207.00M	-348.00M	67.90M	51.28M	202.60M	82.00M
Cash Flow
Free Cash Flow	131.00M	7.00M	-368.00M	-9.82M	313.55M	-210.00M
Operating Cash Flow	189.00M	36.00M	-315.00M	-3.93M	346.97M	-205.73M
Investing Cash Flow	-31.41M	69.00M	-100.36M	-218.95M	-13.76M	-4.26M
Financing Cash Flow	977.13K	-102.00M	-46.00M	-98.18M	-92.39M	-10.66M

Indivior Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 32.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDV, the sentiment is Positive. The current price of 32 is above the 20-day moving average (MA) of 25.75, above the 50-day MA of 24.54, and above the 200-day MA of 15.96, indicating a bullish trend. The MACD of 1.67 indicates Negative momentum. The RSI at 85.12 is Negative, neither overbought nor oversold. The STOCH value of 91.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INDV.

Indivior Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPN	74 Outperform	$3.20B	49.82	6.38%	―	5.55%	1145.24%
AMPH	67 Neutral	$1.17B	9.46	18.32%	―	1.37%	-18.10%
ANIP	66 Neutral	$2.04B	―	-2.82%	―	38.68%	-160.14%
INDV	61 Neutral	$4.00B	31.86	―	―	-0.25%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCRX	51 Neutral	$1.01B	―	-15.57%	―	2.25%	-301.59%
EVO	48 Neutral	$1.45B	―	-16.34%	―	-1.03%	8.13%

Indivior Corporate Events

Indivior PLC Reports Q3 2025 Results and Optimizes Strategy

Indivior PLC is a pharmaceutical company focused on developing treatments for opioid use disorder (OUD), aiming to transform OUD from a crisis to a recognized chronic disease. The company recently reported its financial results for the third quarter of 2025, highlighting a 2% year-over-year increase in total net revenue to $314 million and a significant 15% rise in SUBLOCADE net revenue to $219 million. Indivior also announced strategic initiatives, including the optimization of its Rest of World (ROW) business and the discontinuation of sales and marketing support for OPVEE.

Indivior Raises 2025 Guidance Amid Strategic Moves

Indivior reported its third-quarter 2025 financial results, showing a 2% year-over-year increase in total net revenue to $314 million, driven by a 15% rise in SUBLOCADE’s net revenue. The company has raised its full-year 2025 financial guidance, expecting significant growth in adjusted EBITDA. Indivior is optimizing its Rest of World business by exiting several non-U.S. markets and plans to redomicile in the U.S. These strategic moves are expected to generate substantial operating expense savings and improve cash generation starting in 2026.

The most recent analyst rating on (INDV) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.

Indivior Announces Redomiciliation to U.S. from U.K.

On October 1, 2025, Indivior PLC announced its intention to redomicile from the U.K. to the U.S. by establishing a new parent company, Indivior Pharmaceuticals, Inc., in Delaware. This strategic move follows its Nasdaq listing and aims to enhance its U.S. capital market presence, simplify governance, and align with U.S. health policy stakeholders. The redomiciliation process involves a U.K. court-sanctioned scheme of arrangement and requires shareholder approval, with the transition expected to be completed by late January 2026. This change is anticipated to position Indivior as a U.S.-based treatment innovator, facilitating collaboration on advancing its opioid use disorder treatment, SUBLOCADE®.

The most recent analyst rating on (INDV) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.

Indivior PLC Raises 2025 Financial Guidance Amid Strong Q2 Performance

Indivior PLC is a global pharmaceutical company dedicated to developing medicines for opioid use disorder (OUD), with a strong presence in over 30 countries and a focus on transforming OUD into a recognized and treated chronic disease.

Indivior Launches Action Agenda for Business Enhancement

Indivior PLC has launched the Indivior Action Agenda, a multi-year operational roadmap to enhance its business potential and impact on opioid use disorder treatment. As part of Phase 1, the company is implementing initiatives to simplify its organization, including headcount reductions and real estate consolidations, expecting to incur restructuring charges of $39 to $50 million in 2025. Additionally, Indivior is exploring strategic alternatives for OPVEE® and its non-U.S. business, which could lead to further cost savings.

The most recent analyst rating on (INDV) stock is a Hold with a $1288.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.

Indivior Updates CFO Employment Agreements

On August 20, 2025, Indivior PLC updated its employment agreements with CFO Ryan Preblick to align with current U.S. executive agreements, without altering his compensation or responsibilities. The new agreements include an annual base salary of $558,819, a cash bonus opportunity, and potential long-term incentive awards, reflecting the company’s commitment to maintaining competitive executive compensation structures.

The most recent analyst rating on (INDV) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.

Indivior Raises 2025 Guidance After Strong Q2 Results

On July 31, 2025, Indivior reported its second-quarter financial results, showing a total net revenue of $302 million, with SUBLOCADE net revenue increasing by 9% year-over-year. The company raised its full-year 2025 financial guidance due to better-than-expected performance, with expectations for total net revenue and adjusted EBITDA increasing significantly. Indivior is implementing Phase 1 of its Action Agenda to grow U.S. SUBLOCADE revenue and streamline operations, positioning itself for future growth. The company also announced its inclusion in the Russell Equity Indexes and completed its transition to trading exclusively on Nasdaq.

The most recent analyst rating on (INDV) stock is a Buy with a $1400.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.